Although the addition of IV Dexamethasone to continued ranibizumab therapy reduces retinal thickness, it does not improve vision in patients with diabetic macular edema (DME), shows the findings of a recent study published in JAMA Ophthalmology. For diabetic macular edema (DME), IV ranibizumab (anti-vascular endothelial growth factor) improves visual acuity and limits retinal thickening. However, edema and reduced visual acuity persist almost 66% of eyes treated with at least six-monthly injections.
Recently, a clinical trial compared the efficacy of continued ranibizumab therapy alone vs continued ranibizumab plus IV dexamethasone in persistent DME. Study Design Their study included 129 eyes of 116 patients with persistent DME and reduced visual acuity despite previous anti-VEGF therapy. Treatment Groups The studied eyes were randomly assigned to following two groups: Combination group…
